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Abstract
In 2006, a new variant of Chlamydia trachomatis (nvCT) was discovered in Sweden that was not detectable with Abbott m2000 (Abbott)
and Amplicor/COBAS Amplicor/TaqMan48 (Roche). The proportion of nvCT was 20–64% of the detected Chlamydia cases in counties
using Abbott/Roche test systems. Although the ProbeTec system from Becton Dickinson (BD) could detect nvCT, the proportion of
nvCT in counties using BD was 7–19%. The objective of the current study was to follow the nvCT proportions from 2007 to 2009 in
two counties that used Roche and had introduced test systems able to detect nvCT in late 2006. The nvCT was also followed in two
counties that used BD, and in all four counties the effect of nvCT on the serotype distribution of C. trachomatis wild-type strains was
analysed. A total of 2576 specimens positive for C. trachomatis were collected in the four counties at three time points, and analysed
for nvCT and serotype E. The proportion of nvCT declined significantly in the two counties using Roche, from 65% and 48% in 2007 to
24% for both counties in 2009 (p <0.001). The nvCT proportion increased in Norrbotten county, which used BD, from 9% in 2007 to
19% in 2009 (p 0.03). In Uppsala county, which also used BD but was surrounded by counties using detection systems from Roche, the
proportion of nvCT declined from 24% in 2007 to 18% in 2009 (p <0.03). No major difference in the level of serotype E was seen. The
proportion of nvCT seems to rapidly converge in the Swedish counties after the selective diagnostic advantage for nvCT has been lost
in the Abbott/Roche counties.
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Introduction
A new variant of Chlamydia trachomatis (nvCT) was discov-
ered in Sweden in 2006 that had a 377-bp deletion in the
cryptic plasmid [1]. The deleted area included the target
sequence used by nucleic acid amplification tests (NAATs)
for C. trachomatis manufactured by two commercial compa-
nies, Abbott m2000 (Abbott) and Amplicor/COBAS Ampli-
cor/TaqMan48 (Roche). This deletion resulted in several
thousand false-negative results, and the proportion of nvCT
recorded was between 20% and 64% in counties using test
systems that were unable to detect nvCT in 2006 and early
2007 [2]. The third NAAT used in Sweden, apart from
Abbott/Roche, was the ProbeTec system from Becton
Dickinson (BD). This system has always been able to detect
nvCT, because another target region on the cryptic plasmid
is used. The proportion of nvCT in counties using BD was
between 7% and 19% [2] during the same time period.
The major aim of this study was to investigate the preva-
lence of nvCT in two counties that were unable to detect
this variant in 2006 (O¨rebro and Dalarna, using Roche) and
follow the proportions of nvCT after the introduction of test
systems able to detect nvCT in 2007. The proportion of
nvCT in two counties with effective detection systems even
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before 2006 (Uppsala and Norrbotten, using BD) was also
determined.
C. trachomatis strains are divided into 19 serovars on the
basis of the major outer membrane protein. The nvCT is
serotype E, which is the dominant serotype in Sweden
among wild-type C. trachomatis (wtCT) [3–5]. A second aim
of the present study was to investigate whether the reduc-
tion of wtCT seen in some counties using Abbott/Roche in
2006 [6] had an effect on the serotype distribution among
wtCT. The proportion of serotype E among wtCT was
determined and compared between counties with high or
low proportions of nvCT.
Materials and Methods
Specimens
Between 115 and 278 consecutive C. trachomatis-positive
specimens (one per patient) were collected for each county
and time-point. In total, 2576 specimens were analysed, and
78 of these were untypeable (Dalarna, n = 16; Norrbotten,
n = 24; Uppsala, n = 15; O¨rebro, n = 23) and excluded from
analysis. The time periods for specimen collection are speci-
fied in Table 1. Only urine samples were collected from
Norrbotten at the first time-point in 2007. Additional data
on gender, age and clinical setting of diagnoses were col-
lected from medical records.
DNA extraction
In Dalarna and O¨rebro, the MagNa Pure (Roche) extraction
robot was used for specimens analysed in 2007 and 2008.
In 2009, the Bullet Bugs’n Beads kit on the robot NorDiag
Bullet (NorDiag ASA) was used. DNA from urine speci-
mens collected in Norrbotten and Uppsala was extracted
with the M48 biorobot (Qiagen). Lysate from swab samples
analysed with BD was diluted ten times before PCR, and
if negative in PCR, extracted with the M48 biorobot
(Qiagen).
PCR
A duplex PCR that simultaneously detected the deletion on
the cryptic plasmid and the ompA gene of serotype E was
developed. A primer pair from Ripa et al. [7] amplified the
region of the deletion in the cryptic plasmid. Amplification of
nvCT resulted in a 161-bp fragment, and specimens without
the deletion had a PCR product of 538 bp.
The serotype E specimens were identified by the primers
CtrEF (5¢-TCAAAGCACGGTCAAAACGAATT-3¢) and
CtrER2 (5¢-CATCAGTTCCTGCTATGAGTG-3¢), targeting
ompA and amplifying a PCR product of 278 bp. The reaction
mixture contained 0.4 lM each primer, 0.2 mM dNTP,
2 mM MgCl2 and 0.75 U of HotStarTaq DNA Polymerase
(Qiagen) in a 25-lL reaction mixture. The temperature
profile was as follows: initial denaturation for 15 min at
94C, followed by 40 cycles of denaturation for 30 s at
94C, annealing for 30 s at 55C and elongation for 90 s
at 72C. The amplification was terminated with elongation
for 7 min at 72C. The PCR products were separated on a
1% agarose gel stained with ethidium bromide. Samples with
two bands of 161 bp and 278 bp were interpreted as nvCT.
Samples with only a 538-bp band were interpreted as non-
serotype E wtCT, and samples with the 538-bp and an addi-
tional 278-bp band were interpreted as wtCT serotype E.
Specimens were extracted again if the bands were absent,
weak or aberrant. If they displayed absent, weak or aberrant
bands after a second analysis, the specimens were classified
as untypeable and excluded from study.
A subset of 13 specimens, eight from Uppsala and five
from O¨rebro, was analysed with multilocus sequence typing
(MLST) [8].
Reported cases of C. trachomatis
Information about the reported number of C. trachomatis
cases and the number of tests performed was obtained from
the Swedish Institute for Infectious Disease Control (SMI,
http://www.smittskyddsinstitutet.se, July 2009). The incidence
was defined as number of cases from February to June per
TABLE 1. Time-points for speci-
men collection in the four counties
County (diagnostic system)
Time-points
2007 2008 2009
Dalarna (Roche) 25 Jan. to 23 Feb.
(n = 204)
22 Jan. to 24 Mar.
(n = 204)
2 Feb. to 2 Apr.
(n = 172)
Norrbotten (BD) 28 Nov. (2006) to 9 Feb.
(n = 115)
1 Feb. to 21 May
(n = 242)
2 Feb. to 2 Apr.
(n = 190)
Uppsala (BD) 14 Nov. (2006) to 14 Feb.
(n = 260)
21 Jan. to 27 Mar.
(n = 234)
2 Feb. to 9 Apr.
(n = 217)
O¨rebro (Roche) 1 Feb. to 29 Apr.
(n = 227)
1 Feb. to 30 Apr.
(n = 278)
1 Feb. to 30 Apr.
(n = 233)
BD, Becton Dickinson.
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100 000 inhabitants and was calculated for each county and
time point. The same time period was used for all years to
avoid seasonal changes, and January was excluded because
adequate testing was not available in many counties in
January 2007. The period from July to December was
excluded because of the absence of data for 2009.
Statistics
The chi-square test was used to compare proportions of
nvCT. The calculations were performed with Minitab 15
(Minitab, Coventry, U.K.) software.
Ethics
The study was performed according to the Declaration of
Helsinki II and approved by the Regional Ethical Review
Board in Uppsala, Sweden.
Results
Altogether, 2576 C. trachomatis-positive specimens were anal-
ysed; 78 (3%) of these were untypeable and excluded from
analysis. The proportion of nvCT significantly decreased in
counties using Roche from 2007 to 2009 (Fig. 1a): in Dalarna
from 65% to 51% in 2008 (p 0.005) and then to 24%
(p <0.001), and in O¨rebro from 48% to 37% in 2008
(p 0.013) and then to 24% (p 0.001). An opposite trend was
seen in Norrbotten, where BD was used: the proportion of
nvCT increased from 9% to 13% in 2008 and then to 19% in
2009. A significant result was only obtained when the 2007
and 2009 time points were compared (p 0.029), probably
because of the small number of samples in 2007 and a
weaker trend. The level in Uppsala was stable from 2007
(24%) to 2008 (26%), but then significantly declined to 18%
in 2009 (p 0.025).
The incidence of C. trachomatis, measured as the number
of cases diagnosed from February to June, was relatively sim-
ilar in Norrbotten, Uppsala and O¨rebro, but it was much
higher in Dalarna in 2007 (Fig. 1b). However, the incidence
in Dalarna declined dramatically in 2008, and the differences
in incidence between the four counties were decreasing in
2009.
To determine whether a high proportion of nvCT influ-
enced the serovar distribution, the proportion of serotype E
among wtCT specimens was determined (Fig. 1c). The pro-
portion of serotype E varied between 59% and 69% in Norr-
botten, which was higher than the levels in the other
counties, where the proportion varied between 35% and
62%. No difference in the proportion of wtCT serotype E
was seen between Dalarna and Uppsala in 2007 and 2008,
despite the difference in proportion of nvCT at the time.
The proportion of wtCT serotype E in all four counties was
more similar in 2007 than in 2009, and an opposite trend
was seen in the proportion of nvCT.
A subset of 13 nvCT specimens collected in Uppsala
(n = 8) and O¨rebro (n = 5) in 2009 was genotyped with
MLST. All specimens had the same MLST profile, with the
designation 21 (hctB), 19 (CT058), 1 (CT144), 2 (CT172)
and 1 (pbpB) in our system (C. trachomatis MLST database.
http://mlstdb.bmc.uu.se, February 2010).
The proportion of nvCT was compared for different gen-
ders, age groups and clinical types (Table 2). The persons
(a)
(b)
(c)
FIG. 1. (a) Proportion of new variant Chlamydia trachomatis (nvCT)
of all cases positive for C. trachomatis in two counties using the
Roche system (blue/green) and two counties using the Becton Dick-
inson system (BD) (red/yellow). Differences were significant, with
non-overlapping 95% CIs in 2007. (b) Number of diagnosed cases of
C. trachomatis from February to June per 100 000 inhabitants in the
years 2007–2009. (c) Proportion of serotype E among wild-type
C. trachomatis (wtCT) specimens. The time-points for collection of
specimens presented in (a) and (c) are specified in Table 1.
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infected with nvCT were significantly younger in counties
using Roche in both 2007 and 2008 (p <0.05), but not in
2009. This was not seen in counties using BD. The propor-
tion of nvCT was also higher in youth clinics/gynaecology
clinics than in clinics for venereal diseases, antenatal care and
general practice in 2007 and 2009 (p 0.001). No difference in
the proportion of nvCT was seen between the genders.
The positivity rates were calculated on the basis of all
analysed specimens in all counties using Abbott/Roche and
for all counties using BD for the time period 2004–2009, and
are plotted in Fig. 2. The classification was based on the test
method used in each county in 2005 and 2006, i.e. the time
period previous to the discovery of nvCT and before detec-
tion systems were modified. The positivity rate for counties
using Abbott/Roche was almost the same as in counties using
BD in 2004, 7.7% and 8.0%, respectively. The positivity rate
then dropped to 6.6% in counties using Abbott/Roche in
2006, but was stable in counties using BD during the same
period. From 2007, all counties that used Abbott/Roche
could detect nvCT, which resulted in the identification of
previously undetected nvCT cases, and the positivity rate
increased to 9.5%. In the counties that used BD, the positiv-
ity rate also increased to 9.0%. In 2008, the positivity rate
decreased to levels close to those in 2004, both for counties
using Abbott/Roche (8.1%) and for those using BD (8.4%).
Discussion
The level of nvCT has been reported to be much higher in
counties using Abbott/Roche than in counties using BD [2].
We show that the proportion of nvCT in Roche counties
rapidly decreased after re-establishment of effective detec-
tion systems, and treatment and partner notification is now
reaching sexual networks of nvCT. Therefore, the propor-
tion of nvCT in all four counties converged as a con-
sequence of the loss of selective diagnostic advantage for
nvCT in the Roche counties. A similar trend has also been
seen in Ska˚ne county in the south of Sweden. Here, Abbott
has been used since 2006, and the proportion of nvCT
declined from 30% to 15% between 2007 and 2009 [9].
This trend of converging proportions in the Swedish coun-
TABLE 2. Distribution of cases of new variant Chlamydia trachomatis (nvCT) by gender, age and clinic in the four counties.
The chi-square test was used to compare proportions of nvCT within groups
Factor
2007 2008 2009
% nvCT (n/N)a p-value % nvCT (n/N)a p-value % nvCT (n/N)a p-value
Roche
Gender
Male 55 (98/107) NS 40 (86/214) NS 24 (49/201) NS
Female 57 (126/221) 46 (112/246) 24 (48/204)
Age (years)
<20 65 (103/159) 0.047 51 (87/171) 0.002 28 (35/127) NS
20–24 50 (76/151) 44 (85/194) 23 (40/177)
25–30 53 (31/59) 32 (18/56) 26 (12/46)
‡30< 48 (14/29) 21 (8/39) 18 (10/55)
Clinic
Venereal disease 41 (29/70) 0.001 29 (24/82) 0.001 30 (28/94) NS
Youth clinic 68 (112/164) 50 (92/183) 24 (35/148)
Gynaecology 63 (5/8) 67 (12/18) 44 (4/9)
Antenatal/general practice 49 (72/147) 39 (67/173) 20 (29/146)
Other 67 (6/9) 75 (3/4)b 13 (1/8)b
Becton Dickinson
Gender
Male 21 (39/188) NS 21 (45/212) NS 16 (29/177) NS
Female 18 (30/168) 19 (50/257) 19 (42/217)
Age (years)
<20 16 (15/92) NS 21 (24/112) NS 14 (13/90) NS
20–24 24 (39/165) 21 (45/210) 23 (40/176)
25–30 15 (9/60) 13 (11/85) 19 (13/69)
‡30 15 (6/39) 24 (15/62) 8 (5/60)
Clinic
Venereal disease 20 (18/91) NS 28 (20/72) NS 15 (10/66) NS
Youth clinic 21 (26/125) 18 (29/157) 21 (27/127)
Gynaecology 17 (4/24) 18 (6/34) 21 (7/34)
Antenatal/general practice 13 (12/93) 19 (35/184) 16 (26/163)
Other 20 (1/5)b 23 (5/22) 20 (1/5)b
NS, not significant.
an, number of nvCT; N, number of positive C. trachomatis.
bThese figures were excluded from statistical analysis, owing to low numbers.
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ties after the selective diagnostic advantage has been lost is
also supported by the unaltered biological fitness of nvCT
recently identified when nvCT was comprehensively charac-
terized, genetically (nvCT genome sequenced) and pheno-
typically [10].
The proportion of nvCT in Uppsala county appears to be
greatly influenced by the use of Roche tests in surrounding
counties. The level of nvCT in Uppsala increased in 2008,
when the proportion in O¨rebro [11], Dalarna and probably
also other counties was still high. The declining proportion
of nvCT in Uppsala in 2009 mirrors the decline seen in
Dalarna and O¨rebro and most likely also other adjacent
Roche counties. The concurrent decline in the number of
C. trachomatis-positive cases in Dalarna and the lowered
proportion of nvCT indicate that the decline in incidence is
mostly attributable to decline in nvCT. The stable incidence
in O¨rebro indicates that the decrease in nvCT is balanced by
an increase in wtCT.
The proportion of nvCT doubled in Norrbotten during
the study period. Such an increase may reflect sexual con-
tacts with the nvCT-positive persons in counties using
Abbott or Roche, although a delay in appearance was seen.
This is in agreement with a previous study, where we found
that 59% of sexual contacts with C. trachomatis-positive
persons were with individuals living within 10 km [12]. Thus,
when most sex partners live in the neighbourhood, it takes
time to import and spread a new variant, especially to a
county such as Norrbotten, which has a low population den-
sity and is situated in the northernmost part of Sweden, and
where the nearest county, Va¨sterbotten, is also using BD.
Persons acting as spatial bridgers have been shown to fuel
epidemics [13,14], and may also be important for the spread
of nvCT. The importance of spatial bridgers may also be rel-
evant for the spread of nvCT to other countries. To date,
there have been only a few reports of nvCT cases in other
countries, even though the nvCT proportion in Sweden has
been high for several years; however, most of the studies
were conducted soon after the discovery of nvCT in 2006,
and it is possible that nvCT may have spread to other coun-
tries, especially since many laboratories still use test systems
that cannot detect nvCT [15,16]. There are, for instance,
indications of increasing numbers of nvCT in Norway [17].
The choice of partner and cultural aspects may also have an
impact. As previously reported, very few nvCT cases have
been detected in Copenhagen in Denmark, although the pro-
portion of nvCT has been over 25% on the other side of the
bridge in Malmo¨, Sweden [6,18].
The number of nvCT cases that escaped detection and
treatment in Sweden was estimated to be 8000 in 2006 [6].
The major outer membrane protein MOMP is highly immuno-
genic, and infections that resolve without treatment have
been shown to give rise to strain-specific immunity [19]. The
nvCT is serotype E, the most common serotype in Sweden
[3–5], and the high number of untreated nvCT cases might
therefore be capable of reducing the number of wtCT sero-
type E in counties with high numbers of nvCT. However, in
this study, no clear difference in the proportion of wtCT
serotype E was seen between counties with high and low
proportions of nvCT. Another study, based on specimens
from O¨rebro [20], determined the serotype distribution
before the introduction of nvCT in 1999–2000 and com-
pared this with the distribution in 2006. A similar serotype
distribution was seen after the introduction of nvCT in 2006,
when the nvCT specimens were excluded. Thus, if nvCT is
able to outcompete wtCT, which seems unlikely, it appears
to influence all serotypes in the same way.
The spread of nvCT has been considered to be clonal
when analysed with highly discriminatory genotyping meth-
ods. MLST analysis of 13 nvCT specimens collected in
O¨rebro and Uppsala in 2009 gave the same MLST profile as
in 76 nvCT specimens collected in 2006–2007 [2,20]. The
sequence of the ompA gene in all 13 specimens was also
identical to the predominant sequence in the nvCT speci-
mens from 2006 [2,20]. Similar results have been obtained
with variable-number tandem repeat analysis of 33 nvCT
specimens [21]. Thus, the clonal nature of nvCT has been
confirmed in the present study.
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FIG. 2. Positivity rate for C. trachomatis for different diagnostic
methods in Sweden from 2004 to 2008. The classification of test
method was based on the method used in 2005 and 2006, i.e. the
time period prior to the discovery of new variant Chlamydia tracho-
matis and before detection systems were modified. Most counties
with Abbott/Roche systems also had such systems in 2004. The posi-
tivity rate was calculated as the number of diagnosed C. trachomatis
cases divided by the total number of tests.
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Strains without the cryptic plasmid are not detectable by
many NAATs, and have the potential to spread in a similar
way to nvCT in Sweden. There are reports of plasmid-free
strains from different countries, but these represent very
rare, sporadic cases [22,23] and have not, unlike nvCT in
Sweden, been reported to constitute a large proportion of
the C. trachomatis cases. The function of the cryptic plasmid
is not fully understood, but it is predicted to be a virulence
factor [24]. However, no major biological implications of
the 377-bp deletion and the duplication of 44 bp identified
in the cryptic plasmid of nvCT [25] have yet been found.
Furthermore, the biological fitness of nvCT is also unal-
tered [10].
The high number of nvCT cases that escaped detection
and treatment in Sweden for several years resulted in an
unknown number of salpingitis cases. Analysis of the national
inpatient registry for the years 1998–2008 does not reveal
an increased number of salpingitis episodes in counties using
Abbott/Roche tests prior to 2006, and this is in line with a
recent study of nvCT and clinical manifestations in southern
Sweden [26]. Actually, the rate of salpingitis cases related to
the number of Chlamydia cases is also very low in other
recent studies [27–29], and indicates that it is difficult to ana-
lyse the impact of nvCT on complications. Ectopic pregnancy
is an endpoint that is easier to assess, but is reported later,
and future studies may indicate the consequences of undiag-
nosed nvCT infections.
In Sweden, the reported incidence of C. trachomatis infec-
tions has increased since 1997, but the trend was inter-
rupted by the emergence of nvCT. After implementation of
adequate detection systems, a sharp increase was seen in
2007. This was followed by a significant decrease in 2008
and 2009. This clearly shows that the widespread Chlamydia
testing, treatment and mandatory partner notification in
Sweden has had an effect on the prevalence. Primary preven-
tion initiatives to change sexual lifestyles have been rein-
forced in recent years, and may have contributed to the
declining Chlamydia infection rates. A national action plan for
Chlamydia prevention was declared in 2009 [30]. It is still too
early to assess whether these measures will lead to a contin-
ued decrease in Chlamydia infections. The present Chlamydia
rates are still three-fold higher than in 1997 and well above
the rates when nvCT emerged.
In conclusion, both the proportion of nvCT and the inci-
dence of C. trachomatis are converging in the four counties
now that nvCT is detected by all diagnostic systems used in
Sweden. The trends in this study are mostly a result of
equalization within Sweden, after the irregularity between
counties in 2007 caused by the inability to detect nvCT.
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